Biotechnology in the United States
Published: August 2013 · Publisher: MarketLine
Biotechnology in the United States industry profile provides top-line qualitative and quantitative summary information including: market size (value 2008-12, and forecast to 2017).
- Description
- Companies Mentioned
- Table of Contents
- Ask a Question
Introduction
Biotechnology in the United States industry profile provides top-line qualitative and quantitative summary information including: market size (value 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the United States biotechnology market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
*The biotechnology market consists of the development, manufacturing, and marketing of products based on advanced biotechnology research.
*The US biotechnology market had total revenues of $101.4bn in 2012, representing a compound annual growth rate (CAGR) of 9.7% between 2008 and 2012.
*The US Federal Reserve stimulus, which first began in early 2009, has helped biotechnology companies in America gain popularity after years of being ignored by investors.
*The performance of the market is forecast to decelerate, with an anticipated CAGR of 8.2% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $150.1bn by the end of 2017.
Features
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the biotechnology market in the United States
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the biotechnology market in the United States
Leading company profiles reveal details of key biotechnology market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the United States biotechnology market with five year forecasts
Macroeconomic indicators provide insight into general trends within the United States economy
Key Questions Answered
What was the size of the United States biotechnology market by value in 2012?
What will be the size of the United States biotechnology market in 2017?
What factors are affecting the strength of competition in the United States biotechnology market?
How has the market performed over the last five years?
What are the main segments that make up the United States's biotechnology market?
Biotechnology in the United States industry profile provides top-line qualitative and quantitative summary information including: market size (value 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the United States biotechnology market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
*The biotechnology market consists of the development, manufacturing, and marketing of products based on advanced biotechnology research.
*The US biotechnology market had total revenues of $101.4bn in 2012, representing a compound annual growth rate (CAGR) of 9.7% between 2008 and 2012.
*The US Federal Reserve stimulus, which first began in early 2009, has helped biotechnology companies in America gain popularity after years of being ignored by investors.
*The performance of the market is forecast to decelerate, with an anticipated CAGR of 8.2% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $150.1bn by the end of 2017.
Features
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the biotechnology market in the United States
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the biotechnology market in the United States
Leading company profiles reveal details of key biotechnology market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the United States biotechnology market with five year forecasts
Macroeconomic indicators provide insight into general trends within the United States economy
Key Questions Answered
What was the size of the United States biotechnology market by value in 2012?
What will be the size of the United States biotechnology market in 2017?
What factors are affecting the strength of competition in the United States biotechnology market?
How has the market performed over the last five years?
What are the main segments that make up the United States's biotechnology market?
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.
Amgen, Inc., Baxter International Inc., Biogen Idec, Inc. and Merck & Co., Inc.
TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Category segmentation 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market Segmentation 9
Category segmentation 9
Geography segmentation 10
Market Outlook 11
Market value forecast 11
Five Forces Analysis 12
Summary 12
Buyer power 13
Supplier power 15
New entrants 16
Threat of substitutes 18
Degree of rivalry 19
Leading Companies 20
Amgen, Inc. 20
Baxter International Inc. 23
Biogen Idec, Inc. 26
Merck & Co., Inc. 29
Macroeconomic Indicators 32
Country Data 32
Appendix 34
Methodology 34
Industry associations 35
Related research 35
LIST OF TABLES
Table 1: United States biotechnology market value: $ billion, 2008–12 8
Table 2: United States biotechnology market category segmentation: $ billion, 2012 9
Table 3: United States biotechnology market geography segmentation: $ billion, 2012 10
Table 4: United States biotechnology market value forecast: $ billion, 2012–17 11
Table 5: Amgen, Inc.: key facts 20
Table 6: Amgen, Inc.: key financials ($) 21
Table 7: Amgen, Inc.: key financial ratios 21
Table 8: Baxter International Inc.: key facts 23
Table 9: Baxter International Inc.: key financials ($) 24
Table 10: Baxter International Inc.: key financial ratios 24
Table 11: Biogen Idec, Inc.: key facts 26
Table 12: Biogen Idec, Inc.: key financials ($) 27
Table 13: Biogen Idec, Inc.: key financial ratios 27
Table 14: Merck & Co., Inc.: key facts 29
Table 15: Merck & Co., Inc.: key financials ($) 30
Table 16: Merck & Co., Inc.: key financial ratios 30
Table 17: United States size of population (million), 2008–12 32
Table 18: United States gdp (constant 2000 prices, $ billion), 2008–12 32
Table 19: United States gdp (current prices, $ billion), 2008–12 32
Table 20: United States inflation, 2008–12 33
Table 21: United States consumer price index (absolute), 2008–12 33
Table 22: United States exchange rate, 2008–12 33
LIST OF FIGURES
Figure 1: United States biotechnology market value: $ billion, 2008–12 8
Figure 2: United States biotechnology market category segmentation: % share, by value, 2012 9
Figure 3: United States biotechnology market geography segmentation: % share, by value, 2012 10
Figure 4: United States biotechnology market value forecast: $ billion, 2012–17 11
Figure 5: Forces driving competition in the biotechnology market in the United States, 2012 12
Figure 6: Drivers of buyer power in the biotechnology market in the United States, 2012 13
Figure 7: Drivers of supplier power in the biotechnology market in the United States, 2012 15
Figure 8: Factors influencing the likelihood of new entrants in the biotechnology market in the United States, 2012 16
Figure 9: Factors influencing the threat of substitutes in the biotechnology market in the United States, 2012 18
Figure 10: Drivers of degree of rivalry in the biotechnology market in the United States, 2012 19
Figure 11: Amgen, Inc.: revenues & profitability 22
Figure 12: Amgen, Inc.: assets & liabilities 22
Figure 13: Baxter International Inc.: revenues & profitability 24
Figure 14: Baxter International Inc.: assets & liabilities 25
Figure 15: Biogen Idec, Inc.: revenues & profitability 27
Figure 16: Biogen Idec, Inc.: assets & liabilities 28
Figure 17: Merck & Co., Inc.: revenues & profitability 31
Figure 18: Merck & Co., Inc.: assets & liabilities 31
Executive Summary 2
Market value 2
Market value forecast 2
Category segmentation 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market Segmentation 9
Category segmentation 9
Geography segmentation 10
Market Outlook 11
Market value forecast 11
Five Forces Analysis 12
Summary 12
Buyer power 13
Supplier power 15
New entrants 16
Threat of substitutes 18
Degree of rivalry 19
Leading Companies 20
Amgen, Inc. 20
Baxter International Inc. 23
Biogen Idec, Inc. 26
Merck & Co., Inc. 29
Macroeconomic Indicators 32
Country Data 32
Appendix 34
Methodology 34
Industry associations 35
Related research 35
LIST OF TABLES
Table 1: United States biotechnology market value: $ billion, 2008–12 8
Table 2: United States biotechnology market category segmentation: $ billion, 2012 9
Table 3: United States biotechnology market geography segmentation: $ billion, 2012 10
Table 4: United States biotechnology market value forecast: $ billion, 2012–17 11
Table 5: Amgen, Inc.: key facts 20
Table 6: Amgen, Inc.: key financials ($) 21
Table 7: Amgen, Inc.: key financial ratios 21
Table 8: Baxter International Inc.: key facts 23
Table 9: Baxter International Inc.: key financials ($) 24
Table 10: Baxter International Inc.: key financial ratios 24
Table 11: Biogen Idec, Inc.: key facts 26
Table 12: Biogen Idec, Inc.: key financials ($) 27
Table 13: Biogen Idec, Inc.: key financial ratios 27
Table 14: Merck & Co., Inc.: key facts 29
Table 15: Merck & Co., Inc.: key financials ($) 30
Table 16: Merck & Co., Inc.: key financial ratios 30
Table 17: United States size of population (million), 2008–12 32
Table 18: United States gdp (constant 2000 prices, $ billion), 2008–12 32
Table 19: United States gdp (current prices, $ billion), 2008–12 32
Table 20: United States inflation, 2008–12 33
Table 21: United States consumer price index (absolute), 2008–12 33
Table 22: United States exchange rate, 2008–12 33
LIST OF FIGURES
Figure 1: United States biotechnology market value: $ billion, 2008–12 8
Figure 2: United States biotechnology market category segmentation: % share, by value, 2012 9
Figure 3: United States biotechnology market geography segmentation: % share, by value, 2012 10
Figure 4: United States biotechnology market value forecast: $ billion, 2012–17 11
Figure 5: Forces driving competition in the biotechnology market in the United States, 2012 12
Figure 6: Drivers of buyer power in the biotechnology market in the United States, 2012 13
Figure 7: Drivers of supplier power in the biotechnology market in the United States, 2012 15
Figure 8: Factors influencing the likelihood of new entrants in the biotechnology market in the United States, 2012 16
Figure 9: Factors influencing the threat of substitutes in the biotechnology market in the United States, 2012 18
Figure 10: Drivers of degree of rivalry in the biotechnology market in the United States, 2012 19
Figure 11: Amgen, Inc.: revenues & profitability 22
Figure 12: Amgen, Inc.: assets & liabilities 22
Figure 13: Baxter International Inc.: revenues & profitability 24
Figure 14: Baxter International Inc.: assets & liabilities 25
Figure 15: Biogen Idec, Inc.: revenues & profitability 27
Figure 16: Biogen Idec, Inc.: assets & liabilities 28
Figure 17: Merck & Co., Inc.: revenues & profitability 31
Figure 18: Merck & Co., Inc.: assets & liabilities 31
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.